“Our Inflectra share was 2.3% of the overall infliximab volume,” including both patients who had not used infliximab before and those who switched to Inflectra.
Tag: Renflexis
What Happens When Switching Among Biosimilars?
A health plan would not likely cover both infliximab biosimilars and the reference product. At some point, the plan will seek a contract that leverages marketshare.
No Clear Winner on Supreme Court’s Biosimilar Hearing Day
Despite the fact that the arguments at Wednesday's Supreme Court wrestling match on the patent dance and 180-day notification issue went into overtime, there was no clear winner discernable in Amgen v. Sandoz.
FDA Approves Second Infliximab Biosimilar
On April 21, 2017, the US Food and Drug Administration (FDA) gave its nod to a new biosimilar version of infliximab, and will compete against the originator product Remicade®. Manufactured by Samsung Bioepis, it will be marketed by Merck in the US as Renflexis™.